-$0.11 Earnings Per Share Expected for Viking Therapeutics Inc (VKTX) This Quarter

Equities analysts expect Viking Therapeutics Inc (NASDAQ:VKTX) to post earnings of ($0.11) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Viking Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.13). Viking Therapeutics posted earnings per share of ($0.22) in the same quarter last year, which would indicate a positive year over year growth rate of 50%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, November 14th.

On average, analysts expect that Viking Therapeutics will report full-year earnings of ($0.44) per share for the current financial year, with EPS estimates ranging from ($0.47) to ($0.41). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.48) per share, with EPS estimates ranging from ($0.56) to ($0.39). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Viking Therapeutics.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.02).

A number of equities research analysts have weighed in on the company. Maxim Group reiterated a “buy” rating and issued a $14.00 price objective (up previously from $8.00) on shares of Viking Therapeutics in a research note on Thursday, May 31st. HC Wainwright boosted their price objective on Viking Therapeutics from $11.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, June 1st. Laidlaw boosted their price objective on Viking Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, June 1st. Roth Capital boosted their price objective on Viking Therapeutics from $7.50 to $13.00 and gave the company a “buy” rating in a research note on Friday, June 1st. Finally, Raymond James assumed coverage on Viking Therapeutics in a research note on Thursday, June 28th. They issued an “outperform” rating and a $15.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Viking Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $27.67.

Several institutional investors have recently added to or reduced their stakes in VKTX. Janney Montgomery Scott LLC purchased a new stake in shares of Viking Therapeutics during the second quarter worth approximately $114,000. Strs Ohio purchased a new stake in shares of Viking Therapeutics during the second quarter worth approximately $120,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Viking Therapeutics during the second quarter worth approximately $129,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Viking Therapeutics during the second quarter worth approximately $144,000. Finally, Metropolitan Life Insurance Co. NY purchased a new stake in shares of Viking Therapeutics during the second quarter worth approximately $145,000. Institutional investors and hedge funds own 53.22% of the company’s stock.

Shares of VKTX opened at $18.07 on Thursday. The company has a market capitalization of $1.15 billion, a P/E ratio of -22.87 and a beta of 2.86. Viking Therapeutics has a 52-week low of $1.42 and a 52-week high of $24.00.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

Featured Article: How can investors find ex-dividend dates?

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply